Attach to Form 990 or Form 990-EZ.
See separate instructions.| (i) Name of supported organization |
(ii) EIN |
(iii) Type of organization (described on lines 1- 9 above or IRC section (see instructions)) |
(iv) Is the organization in col. (i) listed in your governing document? |
(v) Did you notify the organization in col. (i) of your support? |
(vi) Is the organization in col. (i) organized in the U.S.? |
(vii) Amount of support? |
|||
|---|---|---|---|---|---|---|---|---|---|
| Yes | No | Yes | No | Yes | No | ||||
| Total | |||||||||
| Calendar year(or fiscal year beginning in) | (a) 2006 | (b) 2007 | (c) 2008 | (d) 2009 | (e) 2010 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") .... | 158,056,293 | 103,328,720 | 209,859,230 | 150,769,181 | 160,093,433 | 782,106,857 |
| 2 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf....... | ||||||
| 3 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | ||||||
| 4 | Total. Add lines 1 through 3.. | 158,056,293 | 103,328,720 | 209,859,230 | 150,769,181 | 160,093,433 | 782,106,857 |
| 5 | The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f).. | 8,296,550 | |||||
| 6 | Public Support. Subtract line 5 from line 4. | 773,810,307 | |||||
| Calendar year(or fiscal year beginning in) | (a) 2006 | (b) 2007 | (c) 2008 | (d) 2009 | (e) 2010 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 7 | Amounts from line 4.. | 158,056,293 | 103,328,720 | 209,859,230 | 150,769,181 | 160,093,433 | 782,106,857 |
| 8 | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | 2,307,807 | 3,955,763 | 1,995,011 | 1,354,102 | 2,037,946 | 11,650,629 |
| 9 | Net income from unrelated business activities, whether or not the business is regularly carried on.. | ||||||
| 10 | Other income. (Explain in Part IV.) Do not include gain or loss from the sale of capital assets.. | 251,335 | 303,840 | 286,205 | 343,630 | 907,754 | 2,092,764 |
| 11 | Total support (Add lines 7 through 10). | 795,850,250 | |||||






| Calendar year(or fiscal year beginning in) | (a) 2006 | (b) 2007 | (c) 2008 | (d) 2009 | (e) 2010 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") . | ||||||
| 2 | Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose...... | ||||||
| 3 | Gross receipts from activities that are not an unrelated trade or business under section 513.. | ||||||
| 4 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf... | ||||||
| 5 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | ||||||
| 6 | Total. Add lines 1 through 5. | ||||||
| 7a | Amounts included on lines 1, 2, and 3 received from disqualified persons... | ||||||
| b | Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year. | ||||||
| c | Add lines 7a and 7b.. | ||||||
| 8 | Public Support (Subtract line 7c from line 6.) | ||||||
| Calendar year (or fiscal year beginning in) | (a) 2006 | (b) 2007 | (c) 2008 | (d) 2009 | (e) 2010 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 9 | Amounts from line 6... | ||||||
| 10a | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | ||||||
| b | Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975. | ||||||
| c | Add lines 10a and 10b. | ||||||
| 11 | Net income from unrelated business activities not included in line 10b, whether or not the business is regularly carried on. | ||||||
| 12 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part IV.) | ||||||
| 13 | Total support (Add lines 9, 10c, 11 and 12.). | ||||||




| Facts And Circumstances Test |
|---|
| Explanation |
|---|
| Software ID: | |
| Software Version: |
Attach to Form 990 or 990-EZ.| Identifier | Return Reference | Explanation |
|---|---|---|
| ORGANIZATION'S MISSION | FORM 990 - PART I, LINE 1 & PART III, LINE 1 | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE CONDUCTS WORLD-CLASS COLLABORATIVE RESEARCH DEDICATED TO FINDING CURES FOR HUMAN DISEASE, IMPROVING THE QUALITY OF LIFE, AND THUS CREATING A LEGACY FOR ITS EMPLOYEES, PARTNERS, DONORS, AND COMMUNITY. |
| PROGRAM SERVICE ACCOMPLISHMENTS | FORM 990, PART III, LINE 4A | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE IS DEDICATED TO DISCOVERING THE FUNDAMENTAL MOLECULAR CAUSES OF DISEASE AND DEVISING THE INNOVATIVE THERAPIES OF TOMORROW. SANFORD-BURNHAM TAKES A UNIQUE, COLLABORATIVE APPROACH TO MEDICAL RESEARCH AND HAS ESTABLISHED MAJOR RESEARCH PROGRAMS IN CANCER, NEURODEGENERATION, DIABETES, AND INFECTIOUS, INFLAMMATORY, AND CHILDHOOD DISEASES. IN THE AREA OF CANCER RESEARCH: IN A STUDY PUBLISHED IN THE JULY 13, 2010 ISSUE OF CANCER CELL, A TEAM OF INVESTIGATORS LED BY ZE'EV RONAI, PH.D. AT SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (SANFORD-BURNHAM) HAS IDENTIFIED A SERIES OF PROTEINS THAT MIGHT MAKE IT EASIER FOR DOCTORS TO BETTER DIAGNOSE THE MORE METASTATIC FORMS OF PROSTATE CANCER. THE STUDY UNCOVERS A PROTEIN NAMED SIAH2, WHICH INITIATES A CASCADE OF MOLECULAR EVENTS THAT TURNS A NON-MALIGNANT TUMOR INTO A METASTATIC NEUROENDOCRINE TUMOR. IN COLLABORATION WITH FOUR OTHER MEDICAL CENTERS ACROSS THE UNITED STATES, DR. RONAI AND HIS COLLEAGUES ANALYZED HUMAN PROSTATE CANCER SAMPLES AND FOUND THAT SIAH2 AND THE OTHER PROTEINS IT TRIGGERS IS DETECTED MORE OFTEN IN THE AGGRESSIVE NEUROENDOCRINE FORMS OF PROSTATE TUMORS THAN IN OTHER TYPES. BY ACTING AS MARKERS FOR PARTICULARLY AGGRESSIVE PROSTATE CANCERS, SIAH2 AND ITS PARTNERS COULD PROVIDE DOCTORS WITH AN EARLY WARNING SIGN FOR TUMORS THAT ARE LIKELY TO METASTASIZE. ZE'EV RONAI, PH.D., AND RESEARCHERS AT SANFORD-BURNHAM RECENTLY USED A MELANOMA MOUSE MODEL, CELL CULTURES AND HUMAN TISSUE SAMPLES TO UNRAVEL THE RELATIONSHIP BETWEEN MITF AND ATF2, A TRANSCRIPTION FACTOR (OR PROTEIN THAT CONTROLS GENE EXPRESSION) THAT IS MORE ACTIVE IN MELANOMAS. THE STUDY, PUBLISHED DECEMBER 23, 2010 IN PLOS GENETICS, DEMONSTRATES THAT THE MITF IS SUBJECT TO NEGATIVE REGULATION BY ATF2, AND SUCH REGULATION IS A KEY DETERMINANT IN MELANOMA DEVELOPMENT. THIS WORK ALSO REVEALS THAT THE RATIO OF ATF2 TO MITF IN THE NUCLEUS OF MELANOMA CELLS CAN PREDICT SURVIVAL IN MELANOMA PATIENTS - RELATIVELY HIGH AMOUNTS OF ATF2 AND CORRESPONDINGLY LOW MITF LEVELS WERE ASSOCIATED WITH A POOR PROGNOSIS. THE STUDY PROVIDES THE FIRST GENETIC EVIDENCE TO SUPPORT THE INITIAL OBSERVATIONS, SHOWING THAT MICE LACKING ATF2 IN MELANOCYTES DO NOT DEVELOP MELANOMA EVEN IF THEY CARRY MUTATIONS SEEN IN HUMAN MELANOMA. RESEARCHERS LED BY DR. RANJAN PERERA AT SANFORD-BURNHAM, AND COLLABORATORS AT THE UNIVERSITY OF QUEENSLAND IN AUSTRALIA, HAVE DISCOVERED THAT LEVELS OF A RELATIVELY UNDERSTUDIED GROUP OF RNAS - LONG, NON-CODING RNA (LNCRNA) - ARE ALTERED IN HUMAN MELANOMA. THEIR STUDY, PUBLISHED ONLINE MAY 10, 2011 BY THE JOURNAL CANCER RESEARCH, SHOWS THAT ONE LNCRNA CALLED SPRY4-IT1 IS ELEVATED IN MELANOMA CELLS, WHERE IT PROMOTES CELLULAR SURVIVAL AND INVASION. TRADITIONALLY, RNA WAS MOSTLY KNOWN AS THE MESSENGER MOLECULE THAT CARRIES PROTEIN-MAKING INSTRUCTIONS FROM A CELL'S NUCLEUS TO THE CYTOPLASM. BUT SCIENTISTS NOW ESTIMATE THAT APPROXIMATELY 97 PERCENT OF HUMAN RNA DOESN'T ACTUALLY CODE FOR PROTEINS AT ALL. IN THE AREA OF NEUROSCIENCE AND AGING RESEARCH: STUART A. LIPTON, M.D., PH.D., AND A TEAM OF RESEARCHERS AT SANFORD-BURNHAM HAVE REVEALED FINDINGS THAT SHOW THAT NITRIC OXIDE, OR NO CAN ACTUALLY JUMP FROM ONE PROTEIN TO ANOTHER IN MOLECULAR PATHWAYS THAT LEAD TO CELLULAR SUICIDE. PREVIOUSLY THEY HAVE SHOWN THAT NO AND RELATED MOLECULES CAN CONTRIBUTE TO EITHER NERVE CELL DEATH OR NERVE CELL SURVIVAL. WITH THIS NEW FINDING, THEY HAVE A MOLECULAR CLUE TO THE CAUSE OF NERVE CELL DEATH IN PARKINSON'S, ALZHEIMER'S, AND HUNTINGTON'S DISEASES, WHICH CAN BE USED TO BETTER DIAGNOSE AND TREAT THESE DISEASES. ALTHOUGH THEIR GENETIC UNDERPINNINGS DIFFER, ALZHEIMER'S DISEASE, PARKINSON'S DISEASE AND HUNTINGTON'S DISEASE ARE ALL CHARACTERIZED BY THE UNTIMELY DEATH OF BRAIN CELLS. THE RESEARCH WAS PUBLISHED IN THE JULY 30, 2010 ISSUE OF MOLECULAR CELL. A SANFORD-BURNHAM TEAM LED BY BARBARA RANSCHT, PH.D. AND PILAR RUIZ-LOZANO, PH.D. REVEALED THAT THE PROTEIN T-CADHERIN IS THE RECEPTOR THAT ANCHORS CARDIOPROTECTIVE HORMONE CALLED ADIPONECTIN TO HEART CELLS. THE STUDY, PUBLISHED NOVEMBER 1, 2010 IN THE JOURNAL OF CLINICAL INVESTIGATION, HELPS ANSWER THE LONGSTANDING QUESTION ABOUT HOW ADIPONECTIN PREVENTS STRESS-INDUCED DAMAGE IN THE HEART. FAT TISSUE IS INCREASINGLY SEEN AS MORE THAN JUST A STORAGE DEPOT - IT'S ALSO AN ACTIVE SECRETORY ORGAN THAT NORMALLY PRODUCES HIGH LEVELS OF ADIPONECTIN. SANFORD-BURNHAM RESEARCHERS LED BY SEAN OLDHAM, PH.D., AND ROLF BODMER, PH.D., RECENTLY CREATED A SIMPLE MODEL TO LINK HIGH-FAT DIET, OBESITY AND HEART DYSFUNCTION. USING FRUIT FLIES, THEY DISCOVERED THAT A PROTEIN CALLED TOR INFLUENCES FAT ACCUMULATION IN THE HEART. THEIR STUDY, PUBLISHED NOVEMBER 3, 2010 IN THE JOURNAL CELL METABOLISM, ALSO DEMONSTRATES THAT MANIPULATING TOR PROTECTS THE HEARTS OF OBESE FLIES FROM DAMAGE CAUSED BY HIGH-FAT DIETS. THEY HAD PREVIOUSLY NOTICED THAT REDUCING TOR HAD A LARGE NUMBER OF BENEFICIAL EFFECTS ON AGING. IN THIS STUDY THE RESEARCHERS ESTABLISHED THE FRUIT FLY AS A MODEL FOR OBESITY CAUSED BY A HIGH-FAT DIET. A TEAM AT SANFORD-BURNHAM, LED BY ROLF BODMER, PH.D. UNRAVELED AN ALTERNATIVE PATHWAY TO LIPOTOXIC CARDIOMYOPATHY, A CONDITION WHERE HEART FUNCTION IS DISRUPTED BY FAT ACCUMULATION IN HEART CELLS. OBESITY AND HIGH-FAT DIETS ARE MAJOR RISK FACTORS FOR LIPOTOXIC CARDIOMYOPATHY. WORKING WITH FRUIT FLIES, THE RESEARCHERS DISCOVERED A GENETIC MECHANISM THAT OCCURS INDEPENDENTLY OF A DIET HIGH IN FAT. THEIR STUDY, PUBLISHED IN THE JANUARY 15, 2011 ISSUE OF GENES & DEVELOPMENT, LAYS THE FOUNDATION FOR THE DEVELOPMENT OF NEW WAYS TO COMBAT LIPOTOXIC CARDIOMYOPATHY AND OTHER TYPES OF HEART DISEASE. A TEAM LED BY SANFORD-BURNHAM RESEARCHER ALEXEY TERSKIKH, PH.D., FOUND THAT EXPRESSION OF A GENE CALLED SOX2 MAINTAINS THE POTENTIAL FOR NEURAL CREST STEM CELLS TO BECOME NEURONS IN THE PERIPHERAL NERVOUS SYSTEM, WHERE THEY INTERFACE WITH MUSCLES AND OTHER ORGANS. EARLY IN EMBRYONIC DEVELOPMENT, THE NEURAL CREST - A TRANSIENT GROUP OF STEM CELLS - GIVES RISE TO PARTS OF THE NERVOUS SYSTEM AND SEVERAL OTHER TISSUES. BUT LITTLE IS KNOWN ABOUT WHAT DETERMINES WHICH CELLS BECOME NEURONS AND WHICH BECOME OTHER CELL TYPES. THEIR RESULTS, PUBLISHED ONLINE MAY 5, 2011 BY THE JOURNAL CELL STEM CELL, COULD HELP BETTER INFORM THERAPIES AIMED AT NEUROCRISTOPATHIES, DISEASES CAUSED BY DEFECTS IN THE NEURAL CREST OR NEURONS, WHICH INCLUDE MICROPHTHALMIA AND CHARGE SYNDROME. |
| IN THE AREA OF DIABETES AND OBESITY RESEARCH: | DANIEL KELLY, M.D., AND HIS COLLEAGUES AT SANFORD-BURNHAM UNVEILED A SURPRISING NEW MODEL FOR STUDYING MUSCLE FUNCTION: THE COUCH POTATO MOUSE. WHILE THESE MICE MAINTAIN NORMAL ACTIVITY AND BODY WEIGHT, THEY DO NOT HAVE THE ENERGY TO EXERCISE. IN THE DECEMBER 1, 2010 ISSUE OF CELL METABOLISM, DR. KELLY'S TEAM REPORTS WHAT HAPPENS WHEN MUSCLE TISSUE LACKS PGC-1, A PROTEIN COACTIVATOR THAT MUSCLES NEED TO CONVERT FUEL INTO ENERGY. NORMALLY, PHYSICAL STIMULATION BOOSTS PGC-1 ACTIVITY IN MUSCLE CELLS, WHICH SWITCHES ON GENES THAT INCREASE FUEL STORAGE, ULTIMATELY LEADING TO "TRAINED" MUSCLE (THE PHYSICAL CONDITION MOST PEOPLE HOPE TO ATTAIN THROUGH EXERCISE). IN OBESE INDIVIDUALS, PGC-1 LEVELS DROP, POSSIBLY FURTHER REDUCING A PERSON'S CAPACITY TO EXERCISE - CREATING A VICIOUS CYCLE. IN THIS STUDY, MICE WITHOUT MUSCLE PGC-1 LOOKED NORMAL AND WALKED AROUND WITHOUT DIFFICULTY, BUT COULD NOT RUN ON A TREADMILL. SANFORD-BURNHAM'S TIMOTHY OSBORNE, PH.D., AND HIS TEAM FOUND THAT A PROTEIN SENSOR KNOWN TO BALANCE CHOLESTEROL SOURCES CAN ALSO ACCESS A PREVIOUSLY UNDERAPPRECIATED CELLULAR FAT STORAGE DEPOT. THE SENSOR, CALLED STEROL REGULATORY ELEMENT-BINDING PROTEIN 2 (SREBP-2), MONITORS CELLULAR CHOLESTEROL LEVELS AND RESPONDS TO LOW LEVELS BY SWITCHING ON GENES THAT ALLOW THE CELL TO EITHER 1) TAKE UP MORE FROM THE BLOODSTREAM OR 2) MANUFACTURE MORE FROM CHOLESTEROL BUILDING BLOCKS INSIDE THE CELL. THE RESEARCHERS ALSO UNCOVERED A THIRD CHOLESTEROL SOURCE ALSO CONTROLLED BY SREBP-2: FAT DROPLETS STORED INSIDE THE CELL ITSELF. THE STUDY WAS PUBLISHED APRIL 6, 2011 IN THE JOURNAL CELL METABOLISM. IN THE AREA OF CHILDREN'S HEALTH RESEARCH: AT SANFORD-BURNHAM, A TEAM OF SCIENTISTS LED BY PIER LORENZO PURI, M.D., PH.D., RECENTLY UNCOVERED THE MOLECULAR MESSENGERS THAT TRANSLATE INFLAMMATORY SIGNALS INTO THE GENETIC CHANGES THAT TELL MUSCLE STEM CELLS TO DIFFERENTIATE. UNDER NORMAL CIRCUMSTANCES, ADULT STEM CELLS RESIDE IN MUSCLE TISSUE, WHERE THEY CAN DIFFERENTIATE INTO A NUMBER OF DIFFERENT CELL TYPES. AFTER AN INJURY (OR EVEN A TOUGH WORKOUT), MUSCLES ARE INFLAMED AS CELLS AND MOLECULES FLOOD THE AREA TO CONTROL DAMAGE AND BEGIN REPAIRS. WHEN CALLED UPON TO REPLACE MUSCLE TISSUE DAMAGED BY INJURY OR GENETIC DISEASE, SOME MUSCLE STEM CELLS DIFFERENTIATE, BECOMING NEW MUSCLE CELLS, WHILE OTHERS MAKE MORE STEM CELLS. WRITING IN THE OCTOBER 8, 2010 ISSUE OF THE JOURNAL CELL STEM CELL, DR. PURI AND COLLEAGUES REVEAL FUNDAMENTAL MECHANISMS THAT COULD BE MANIPULATED TO ENHANCE HOW MUSCLE STEM CELLS REGENERATE INJURED OR DISEASED MUSCLES. THESE FINDINGS COULD LEAD TO NEW TREATMENTS FOR DISEASES LIKE MUSCULAR DYSTROPHY. IN THE AREA OF INFECTIOUS AND INFLAMMATORY DISEASES: A STUDY LED BY ROBERT RICKERT, PH.D., AT SANFORD-BURNHAM EXPLORED THE ROLES OF TWO ENZYMES INVOLVED IN LYMPHOMA, A CANCER OF THE IMMUNE SYSTEM. THE RESEARCH EXPLORED THE ROLE OF THE ENZYMES, CALLED SHIP AND PTEN, IN B CELL GROWTH AND PROLIFERATION. LYMPHOMA IS A CANCER OF THE IMMUNE SYSTEM. WHITE BLOOD CELLS DIVIDE AGAIN AND AGAIN, SPREADING ABNORMALLY THROUGHOUT THE BODY. LYMPHOMAS CAN ARISE FROM TWO TYPES OF WHITE BLOOD CELLS, T CELLS OR B CELLS, WHICH DIVIDE UNCONTROLLABLY WHEN THE MOLECULAR MECHANISMS THAT KEEP THEM IN CHECK GO AWRY. THE RESULTS, PUBLISHED ONLINE ON OCTOBER 18, 2010 IN THE JOURNAL OF EXPERIMENTAL MEDICINE, SHOW THAT SHIP AND PTEN ACT COOPERATIVELY TO SUPPRESS B CELL LYMPHOMA. THIS NEW INFORMATION COULD IMPACT SEVERAL ANTI-LYMPHOMA THERAPIES CURRENTLY IN DEVELOPMENT. | |
| PROCESS USED BY MANAGEMENT AND/OR GOVERNING BODY TO REVIEW FORM 990 | FORM 990, PART VI, LINE 11B | THE 990 IS PREPARED BY THE FINANCE DEPARTMENT. IT IS REVIEWED BY THE INSTITUTE'S TAX ADVISORS, SELECTED MEMBERS OF MANAGEMENT INCLUDING OFFICERS, AND THE AUDIT COMMITTEE OF THE BOARD OF TRUSTEES AND MADE AVAILABLE TO THE MEMBERS OF THE BOARD PRIOR TO FILING. |
| PROCESS USED BY MANAGEMENT AND/OR GOVERNING BODY TO REVIEW FORM 990 | FORM 990, PART VI, LINE 11B | THE 990 IS PREPARED BY THE FINANCE DEPARTMENT. IT IS REVIEWED BY THE INSTITUTE'S TAX ADVISORS, SELECTED MEMBERS OF MANAGEMENT INCLUDING OFFICERS, AND THE AUDIT COMMITTEE OF THE BOARD OF TRUSTEES AND MADE AVAILABLE TO THE MEMBERS OF THE BOARD PRIOR TO FILING. |
| DESCRIPTION OF PROCESS TO MONITOR TRANSACTIONS FOR CONFLICT OF INTEREST | FORM 990, PART VI, QUESTION 12C | ANNUALLY, THE INSTITUTE REQUIRES BOARD OF TRUSTEE APPROVAL OF COMPENSATION ADJUSTMENTS AND TOTAL COMPENSATION LEVELS FOR ALL OFFICERS AND OTHER "DISQUALIFIED PERSONS" (AS DEFINED BY IRC SECTION 4958). THE COMPENSATION COMMITTEE, A COMMITTEE DESIGNATED BY THE BOARD, IS RESPONSIBLE FOR THE PROCESS AND ENGAGING AN INDEPENDENT CONSULTING FIRM TO ASSIST IT IN REVIEWING THE TOTAL COMPENSATION PACKAGES (INCLUDING CASH AND NON-CASH BENEFITS) FOR THESE IDENTIFIED PERSONS. THE CONSULTANT REVIEWS THE VARIOUS TYPES OF DIRECT CASH COMPENSATION INCLUDING BASE SALARIES AND ANNUAL INCENTIVE AWARD OPPORTUNITIES AND PAYMENTS. IN ADDITION, THE CONSULTANT PROVIDES THE COMMITTEE AN ASSESSMENT OF TOTAL COMPENSATION INCLUDING THE CASH COMPONENTS MENTIONED ABOVE, PLUS EXECUTIVE BENEFITS AND PERQUISITES. THE CONSULTANT COLLECTS INFORMATION FROM VARIOUS SURVEY SOURCES COVERING NOT-FOR PROFIT AND FOR-PROFIT ORGANIZATIONS SIMILAR IN SIZE AND REFLECTING THE TALENT MARKETS FROM WHICH THE INSTITUTE DRAWS EXECUTIVE TALENT. THE NUMBER OF FOR-PROFIT ORGANIZATIONS USED IN THE SURVEY PROCESS DOES NOT EXCEED 50% OF THE TOTAL ORGANIZATIONS USED. THE COMPENSATION COMMITTEE UTILIZES THIS STUDY ALONG WITH PERFORMANCE DATA FOR EACH INDIVIDUAL TO SUPPORT THEIR DELIBERATIONS AND REVIEW OF PAY LEVELS IN RELATION TO THE EXECUTIVE COMPENSATION PAY PHILOSOPHY AND THE ORGANIZATION'S MISSION. THE DETERMINATION OF EXECUTIVE COMPENSATION IS ALSO DESIGNED TO MEET THE "REBUTTABLE PRESUMPTION OF REASONABLENESS" STANDARD AS OUTLINED IN THE TREASURY REGULATIONS. DECISIONS BY THE COMMITTEE ARE CONTEMPORANEOUSLY DOCUMENTED. THE COMMITTEE PRESENTS THE STUDY FINDINGS AND THE RESULTING DECISIONS TO THE ENTIRE BOARD OF TRUSTEES. THE INSTITUTE'S EXECUTIVE COMPENSATION PHILOSOPHY, WHICH IS REVIEWED ANNUALLY, IS AS FOLLOWS: TARGET EXECUTIVE BASE SALARY AND TOTAL CASH COMPENSATION IS BETWEEN THE 50TH AND 75TH PERCENTILES BY BLENDING DATA FROM SIMILARLY SIZED BIOTECHNOLOGY ORGANIZATIONS FROM THE NOT-FOR-PROFIT AND FOR-PROFIT SECTOR, RESEARCH INSTITUTES AND LARGE UNIVERSITIES. THE PROCESS WAS LAST COMPLETED ON JUNE 8, 2011 FOR THE FOLLOWING 13 POSITIONS: -EXECUTIVE VICE PRESIDENT, CHIEF ADMINISTRATIVE OFFICER, CHIEF FINANCIAL OFFICER AND TREASURER -SENIOR VICE PRESIDENT, BUSINESS DEVELOPMENT -SENIOR DIRECTOR, IP PROP & LEGAL AFFAIRS AND SECRETARY OF THE BOARD -DIRECTOR, IIDC -SCIENTIFIC DIRECTOR, DIABETES AND OBESITY RESEARCH CENTER -DIRECTOR, NASCR -PRESIDENT/DIRECTOR, CANCER CENTER -CEO |
| PROCESS USED TO DETERMINE COMPENSATION | FORM 990, PART VI, LINES 15A AND 15B | ANNUALLY, THE INSTITUTE REQUIRES BOARD OF TRUSTEE APPROVAL OF COMPENSATION ADJUSTMENTS AND TOTAL COMPENSATION LEVELS FOR ALL OFFICERS AND OTHER "DISQUALIFIED PERSONS" (AS DEFINED BY IRC SECTION 4958). THE COMPENSATION COMMITTEE, A COMMITTEE DESIGNATED BY THE BOARD, IS RESPONSIBLE FOR THE PROCESS AND ENGAGING AN INDEPENDENT CONSULTING FIRM TO ASSIST IT IN REVIEWING THE TOTAL COMPENSATION PACKAGES (INCLUDING CASH AND NON-CASH BENEFITS) FOR THESE IDENTIFIED PERSONS. THE CONSULTANT REVIEWS THE VARIOUS TYPES OF DIRECT CASH COMPENSATION INCLUDING BASE SALARIES AND ANNUAL INCENTIVE AWARD OPPORTUNITIES AND PAYMENTS. IN ADDITION, THE CONSULTANT PROVIDES THE COMMITTEE AN ASSESSMENT OF TOTAL COMPENSATION INCLUDING THE CASH COMPONENTS MENTIONED ABOVE, PLUS EXECUTIVE BENEFITS AND PERQUISITES. THE CONSULTANT COLLECTS INFORMATION FROM VARIOUS SURVEY SOURCES COVERING NOT-FOR PROFIT AND FOR-PROFIT ORGANIZATIONS SIMILAR IN SIZE AND REFLECTING THE TALENT MARKETS FROM WHICH THE INSTITUTE DRAWS EXECUTIVE TALENT. THE NUMBER OF FOR-PROFIT ORGANIZATIONS USED IN THE SURVEY PROCESS DOES NOT EXCEED 50% OF THE TOTAL ORGANIZATIONS USED. THE COMPENSATION COMMITTEE UTILIZES THIS STUDY ALONG WITH PERFORMANCE DATA FOR EACH INDIVIDUAL TO SUPPORT THEIR DELIBERATIONS AND REVIEW OF PAY LEVELS IN RELATION TO THE EXECUTIVE COMPENSATION PAY PHILOSOPHY AND THE ORGANIZATION'S MISSION. THE DETERMINATION OF EXECUTIVE COMPENSATION IS ALSO DESIGNED TO MEET THE "REBUTTABLE PRESUMPTION OF REASONABLENESS" STANDARD AS OUTLINED IN THE TREASURY REGULATIONS. DECISIONS BY THE COMMITTEE ARE CONTEMPORANEOUSLY DOCUMENTED. THE COMMITTEE PRESENTS THE STUDY FINDINGS AND THE RESULTING DECISIONS TO THE ENTIRE BOARD OF TRUSTEES. THE INSTITUTE'S EXECUTIVE COMPENSATION PHILOSOPHY, WHICH IS REVIEWED ANNUALLY, IS AS FOLLOWS: TARGET EXECUTIVE BASE SALARY AND TOTAL CASH COMPENSATION IS BETWEEN THE 50TH AND 75TH PERCENTILES BY BLENDING DATA FROM SIMILARLY SIZED BIOTECHNOLOGY ORGANIZATIONS FROM THE NOT-FOR-PROFIT AND FOR-PROFIT SECTOR, RESEARCH INSTITUTES AND LARGE UNIVERSITIES. THE PROCESS WAS LAST COMPLETED ON JUNE 8, 2011 FOR THE FOLLOWING 13 POSITIONS: -EXECUTIVE VICE PRESIDENT, CHIEF ADMINISTRATIVE OFFICER, CHIEF FINANCIAL OFFICER AND TREASURER -SENIOR VICE PRESIDENT, BUSINESS DEVELOPMENT -SENIOR DIRECTOR, IP PROP & LEGAL AFFAIRS AND SECRETARY OF THE BOARD -DIRECTOR, IIDC -SCIENTIFIC DIRECTOR, DIABETES AND OBESITY RESEARCH CENTER -DIRECTOR, NASCR -PRESIDENT/DIRECTOR, CANCER CENTER -CEO |
| AVAIL OF GOV DOCS, CONFLICT OF INTEREST POLICY & FIN STMTS TO GEN PUBLIC | FORM 990, PART VI, Line 19 | DOCUMENTS ARE AVAILABLE UPON REQUEST. |
| OTHER CHANGES IN NET ASSETS OR FUND BALANCES | FORM 990, PART XI, LINE 5 | NET UNREALIZED GAINS ON INVESTMENTS $4,425,781 UNREALIZED GAIN ON INTEREST RATE SWAP $ 474,895 -------------- TOTAL $4,900,676 |
| Software ID: | |
| Software Version: |